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OBJECTIVE — Clinicians who treat children with type 1 diabetes often try to minimize the
number of daily injections to reduce treatment burden and improve compliance. Despite the
manufacturer’s cautions against mixing glargine with rapid-acting insulin analogs, clinical stud-
ies have failed to demonstrate deleterious effects of mixing on glucose excursions or A1C levels.
However, no formal glucose clamp studies have been performed to determine whether mixing
with glargine has an adverse effect on the early pharmacodynamic action of rapid-acting insulin
in humans.
RESEARCH DESIGN AND METHODS — To examine this question, euglycemic glu-
cose clamps were performed twice, in random order, in 11 youth with type 1 diabetes (age
15.1  3 years, A1C 7.6  0.6%) with 0.2 units/kg lispro and 0.4 units/kg glargine, given either
as separate or as a single mixed injection.
RESULTS — Mixing the two insulins shifted the time action curve to the right, with signiﬁ-
cantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190
min and signiﬁcantly higher values between 270 and 300 min, lowered the GIRmax (separate
7.1  1 vs. mix 3.9  1, P  0.03), and markedly delayed the time to reach GIRmax (separate
116  8 min vs. mix 209  15 min, P  0.004). The GIR area under the curve was signiﬁcantly
lowerafterthemixedinjections.Mixinghadsimilareffectsonplasmainsulinpharmacokinetics.
CONCLUSIONS — These data demonstrate that mixing lispro with glargine markedly ﬂat-
tens the early pharmacodynamic peak of lispro and causes a shift to the right in the GIR curve
changes that might lead to difﬁculties in controlling meal-related glucose excursions.
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nsulin glargine revolutionized the dia-
betes therapy by being the ﬁrst soluble
long-acting insulin analog without a
pronounced peak and with a more pro-
longed time-action curve than NPH insu-
lin (1–4). Basal-bolus therapy with
glargine and rapid-acting insulin analogs
provided patients with greater accuracy
and precision in insulin dosing than was
possiblewithsplit-mixregimensusingin-
termediate-acting insulin suspensions
(5), albeit at the expense of greater num-
bers of required daily insulin injections.
Poor compliance with the requirements
of frequent injections is a major contrib-
uting cause of failure to achieve target
plasma glucose and A1C levels in adoles-
cents with type 1 diabetes using multiple
daily injection regimes (6). Conse-
quently, some pediatric diabetes provid-
ers have opted to decrease the number of
daily injections in youth using multiple
dailyinjectiontherapybymixingglargine
with rapid-acting insulin analogs, despite
company(7)andU.S.FoodandDrugAd-
ministration warnings against doing so.
Recommendations against mixing were
based on preclinical glucose clamp stud-
ies in beagle dogs indicating that the
maximal glucose-lowering effect of regu-
lar insulin was blunted and delayed by
mixing with glargine (8). On the other
hand,threeclinicalstudiesthatexamined
mixing of glargine with rapid-acting ana-
logs in youth with type 1 diabetes did not
demonstrate a change in 24 mean glucose
concentrations or A1C levels (9–11).
However, glucose clamp studies have not
been carried out to determine whether
mixing of rapid-acting insulin analogs
with glargine just before injection alters
the early time-action proﬁle of this com-
bination in patients with type 1 diabetes.
The present study was conducted to ex-
amine this question in adolescents with
type 1 diabetes, since this is the popula-
tion of patients with type 1 diabetes in
whom mixing is most often considered.
RESEARCH DESIGN AND
METHODS— Eleven subjects with
type 1 diabetes (six male and ﬁve female)
who attended the Yale Children’s Type 1
Diabetes Clinic were studied. Eligibility
criteria included a clinical diagnosis of
type 1 diabetes for at least 1 year’s dura-
tion,agerangingfrom11to21years,con-
tinuous subcutaneous insulin infusion
therapy for at least 3 months, A1C
9.0%, BMI 95% for age and sex, and
the ability to comprehend written and
spoken English. Subjects were excluded
for any other medical disease aside from
type 1 diabetes or treated hypothyroid-
ism; use of medications that might affect
glycemic control; pregnancy or breast-
feeding; not consistently using barrier
methods or abstinence as contraception;
or any other condition that in the judg-
ment of the investigators would interfere
with the subject’s or parent’s ability to
provide informed consent or the investi-
gator’s ability to perform the study. The
Yale University Human Investigation
Committee approved the study.
At the initial enrollment visit, the
risks and beneﬁts of the study were ex-
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ents and informed assent from the
subjects were obtained; history and phys-
ical examinations were performed and
A1C was measured.
Procedures
Subjects were admitted to the Yale–New
Haven Hospital Research Unit on the
evening before the euglycemic clamp to
monitor blood glucose levels. An intrave-
nous catheter was placed to measure
bloodglucoselevelshourlyovernightand
insulin dose was adjusted via insulin
pump to achieve glucose levels between
80 and 120 mg/dl on the morning of the
euglycemic clamp.
A second intravenous catheter was
placed on the contralateral arm for infu-
sion of exogenous glucose the following
morning, and subjects were randomized
to receive 0.2 units/kg lispro and 0.4
units/kg glargine in a mixed or nonmixed
fashion.Subjectswhoreceivedbothinsu-
lins mixed in a syringe before the initial
clamp were given separate injections be-
fore the second euglycemic clamp per-
formed within 4 weeks of the ﬁrst clamp
and vice versa. Insulin lispro and glargine
were mixed in the same syringe (Becton
Dickinson insulin syringe with an ultra-
ﬁne needle, 8 mm, 31 gauge; Becton
Dickinson, Franklin Lakes, NJ) at room
temperature immediately before the in-
jection into the deep subcutaneous tissue
of the left arm through a two-ﬁnger pinch
of skin at a 45–90° angle. Subjects were
given insulin glargine from the left arm
and insulin lispro from the right arm on
the day that they were randomized to re-
ceive insulins separately. The infusion of
insulin via the insulin pump was sus-
pended just before the administration of
lispro and glargine.
Plasma glucose levels were measured
every 5 min, and a 20% dextrose infusion
was adjusted to clamp plasma glucose
concentrations between 80 and 90 mg/dl
during5ho ft h estudy, as previously de-
scribed (12). Blood for measurement of
plasma insulin levels was collected every
10 min for the ﬁrst 90 min, every 15 min
for the next 90 min, and every 30 min for
the last 120 min.
Biochemical methods
A1C was measured by the DCA Vantage
Analyzer (Siemens Medical Equipment,
Malvern, PA), plasma glucose by the YSI
Glucose Analyzer, and plasma insulin by
the Mercodia (Mercodia, Uppsala, Swe-
den) iso-insulin enzyme-linked immu-
nosorbent assay (ELISA) test. This assay
has a reported cross-reactivity of 89%
with insulin lispro and 44% with insulin
glargine (13).
Statistical analysis
Statistical comparisons were performed
using GraphPad Prism version 5.0
(GraphPad Software, La Jolla, CA) and
SAS version 9.2 (SAS Institute Cary, NC).
Data are expressed as means  SEM. Ex-
ogenous glucose infusion rate (GIR) ana-
lyzed every 10 min was adjusted for
changes in the glucose space, as previ-
ously described (14). The pharmacody-
namicparametersthatwerecalculatedfor
each clamp study included area under
the curve of the glucose infusion rate
(AUCGIR 0–300), maximum glucose infu-
sion rate (GIRmax), and time to maximum
glucose infusion rate (TGIRmax). Pharma-
cokinetic parameters included AUCins,
peak concentration of insulin (Cins-max),
andtimetoCins-max(Tins-max).Plasmaglu-
cose, pharmacodynamic, and pharmaco-
kinetic parameters were compared using
paired t tests. A mixed-model repeated-
measuresanalysiswasusedtoanalyzedif-
ferences in GIR and plasma insulin levels
between the two studies across time
points. Because there was a signiﬁcant
group  time effect in both GIR (P 
0.001) and plasma insulin (P  0.001)
responses, paired t tests were used to lo-
calize the effects.
RESULTS—At o t a lo f1 1s u b j e c t s
withtype1diabetes,age15.12.9years
and A1C of 7.6  0.6%, were enrolled
and completed both clamp studies.
Plasma glucose levels were similar during
the mixed and separate injection studies
at baseline (121  9 vs. 126  12 mg/dl)
and during the5ho ft h eclamp (95  2
vs. 99  2 mg/dl, respectively). As shown
in Fig. 1, compared with separate injec-
tions, mixing the two insulins signiﬁ-
cantly shifted the time action curve to the
right, with signiﬁcantly lower GIR values
afterthemixedinjectionsbetween60and
190 min and signiﬁcantly higher values
between 270 and 300 min. As shown in
Table 1, mixing signiﬁcantly reduced the
GIRmax (P  0.03), delayed the TGIRmax
(P  0.0001), and decreased overall
AUCGIR 0–300 (P  0.03). As shown in
Fig. 2 and Table 1, mixing lispro with
glargine had pharmacokinetic effects that
were similar to the changes in pharmaco-
dynamics; namely, plasma insulin levels
were lower between 10 and 170 min,
Figure 1—Pharmacodynamic proﬁles. Insulin action, as expressed as GIR, required to maintain
euglycemiaafterastandardbolusof0.2units/kginsulinlisproand0.4units/kgofinsulinglargine
mixedorseparateduringthe5hofstudyareshown.DataaremeansSEM.*Timepointswhere
differences between the two studies were statistically signiﬁcant (P  0.05–0.001).
PKPD of mixing glargine with lispro
1010 DIABETES CARE, VOLUME 33, NUMBER 5, MAY 2010 care.diabetesjournals.orgoverallAUCinsandCins-maxwerereduced,
and Tins-max was delayed.
CONCLUSIONS — Our data dem-
onstrate that the pharmacokinetic and
pharmacodynamic (PKPD) proﬁles of lis-
proinsulinaremarkedlyalteredwhenlis-
proismixedwithglargineinsulin.Mixing
causedamarkeddelayinthepeakinsulin
action compared with when lispro and
glargine were given as separate injections
in this study and in comparison to the
timing of peak lispro action previously
reported in continuous subcutaneous
insulin infusion–treated adolescents after
a similar 0.2 units/kg bolus of lispro insu-
lin alone (12). Moreover, mixing signiﬁ-
cantly diminished the peak lispro effect
(GIRmax), as well as the overall
AUCGIR 0–300, in comparison to corre-
sponding values when the two insulins
were given as separate injections. Com-
paredwithseparateinjections,mixingthe
two insulins resulted in increased GIR
values during the last hour of the clamp,
which was limited to 5 h because of the
difﬁculty of extending the duration
of clamp procedure further in this
age-group.
Paradoxically, determination of the
pharmacokinetic effects of mixing lispro
withglargineismorechallenginginmany
ways than determining the changes in
pharmacodynamics. Many of the avail-
able insulin assays measure only a small
fraction of the total circulating concentra-
tions of analog insulins or have substan-
tial cross-reactivity between analog
insulins. We used the Mercodia iso-
insulin assay in this study because it
detects 80% of circulating lispro con-
centrations and because cross-reactivity
with glargine would be expected to have
only a small effect on the early rise in
plasmainsulinlevelsthatwasbeinginves-
tigated in this study. Based on the ﬁrst-
dosepharmacokineticsofglargine(4)and
the 44% cross-reactivity of glargine in the
iso-insulinassay,themaximumcontribu-
tion of glargine to the measured plasma
levels was likely to be 10 U/ml at any
time during the5ho ft h estudy.
Nevertheless, it is important to em-
phasize that this study does not delineate
the PKPD of insulin glargine due to the
low speciﬁcity of this assay for insulin
glargine and the conﬁned 5-h duration of
our clamp procedure. Despite these limi-
tations, the pharmacokinetic effects of
mixing lispro with glargine paralleled the
changes in pharmacodynamics. It is note-
worthy that the effects of mixing lispro
insulin with glargine in adolescents with
type 1 diabetes in this study were similar
to those observed with mixing of regular
insulin and glargine in prior animal stud-
ies (3).
The ﬁndings of this study are not in-
compatiblewiththoseofpreviousclinical
trials that failed to observe deterioration
in A1C levels or daily glucose proﬁles in
children and adolescents with type 1 dia-
betes when lispro was mixed with
glargine.Weonlystudiedaﬁxed1:2ratio
of lispro to glargine, whereas the fraction
of lispro can be increased in clinical stud-
ies to compensate for the delayed and di-
minished peak action of lispro when it is
mixed with glargine. Moreover, in prac-
tice, the potential adverse effect of mixing
lisproandglargineatdinnermaybeoffset
by greater compliance with the other two
to four injections of lispro insulin that are
required in multiple daily injection regi-
mens. Nevertheless, the alterations in the
timeactionproﬁlesthatwehaveobserved
in this study raise serious concerns that
there will be a greater risk of early post-
prandialhyperglycemiaaftermixeddoses
of lispro and glargine. As important,
when this mixture is used at dinnertime,
thedelayedincreaseintheactionoflispro
5 h after the dose, corresponding to
3–4hafterthebedtimeofyoungchildren
andpossiblywhenparentsarealsoasleep,
Figure 2—Pharmacokinetic proﬁles. Insulin concentration, measured by ELISA with a reported
cross-reactivityof44%forinsulinglargine,forseparateandmixedinjectionsdepictedinmeans
SEM for separate and mixed insulin glargine-lispro injections. *Time points where differences
between the two studies were statistically signiﬁcant (P  0.05–0.001).
Table 1—Pharmacodynamic and pharmacokinetic summary measures after subcutaneous
injection of insulin glargine and lispro in separate or mixed injections
Separate injection Mix injection P
Pharmacodynamics
GIRmax (mg   kg
1   min
1) 7.1  1 3.9  1 0.04
TGIRmax (min) 116  8 209  15 0.001
AUCGIR 0–300 (min) 1,050  202 613  109 0.03
AUCGIR 0–90 (min) 250  32 64  72 0.04
AUCGIR 210–300 (min) 201  36 273  48 0.1
Pharmacokinetics
Cins-max 149  38 53  9 0.04
Tins-max (min) 55  6 106  19 0.04
AUCinsulin 0–300 (min) 27,134  6,088 16,354  4,101 0.01
AUCinsulin 0–90 (min) 10,195  1,965 3,934  857 0.0007
AUCinsulin 210–300 (min) 4,346  1,107 4,775  1,398 0.5
Data are means  SE. P values refer to the signiﬁcance of differences between separate and mixed injections.
Cengiz and Associates
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turnal hypoglycemia.
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